Cancer Immunology – News and Features
News
Oncolytics Biotech® Inc. Receives No Objection Letter from Health Canada to Conduct Phase 3 Trial of REOLYSIN®
The company plans to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with head and neck cancers.
News
Immunovaccine Licenses Clinical Stage Cancer Vaccine from Merck KGaA
Immunovaccine will build on the current on-going Phase 1 study for EMD 640744 by formulating the survivin-based vaccine in its DepoVax™.
News
Rare Hybrid Cell Key to Regulating the Immune System
The discovery could have implications for the efficacy of new therapies that manipulate two immune cell types to treat cancer and rheumatoid arthritis.
News
Vaxon Biotech Successfully Completes its Phase I/II Trial of Vx-001 Cancer Vaccine
Results show Vx-001 vaccine to be safe, strongly immunogenic and clinically active; vaccine is now ready to move to pivotal Phase III trial.
News
Oncos Therapeutics Raises €4 Million from Healthcap to Develop Oncolytic Viruses into Cancer Treatments
Oncos has selected its modified oncolytic adenovirus CGTG-102 as its lead clinical candidate.
News
Fluidigm and Qiagen's SABiosciences Team up to Provide Over 100 PCR Gene Expression Panels for Biomark Systems
Fluidigm Corporation and SABiosciences (a QIAGEN Company) today announced that they have teamed up to create over 100 pathway-focused gene expression panels validated for real-time PCR analysis on the Fluidigm BioMark™ System for Genetic Analysis.
News
immatics Enters Collaboration with Cancer Research UK to Develop Cancer Vaccine
Cancer Research UK will sponsor and conduct a Phase I trial of IMA950 for glioblastoma.
News
Immatics Enters Collaboration with Cancer Research UK to Develop Multi-target Rationally Designed Therapeutic Cancer Vaccine
IMA950 to enter Phase I development for glioblastoma, the most aggressive form of brain cancer
News
QIAGEN Unit and Pfizer Enter Into an Agreement to Develop a Companion Diagnostic for Brain Tumor Patients
The agreement will develop a companion diagnostic test kit for PF-04948568 for the treatment of glioblastoma multiforme.
News
QIAGEN Unit and Pfizer Collaborates to Develop a Companion Diagnostic for Brain Tumor Patients
Both companies have entered into an agreement to develop a companion diagnostic test kit for PF-04948568.
Advertisement
